Neoplasms Clinical Trial
Official title:
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4
Verified date | February 2024 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.
Status | Completed |
Enrollment | 34 |
Est. completion date | April 27, 2015 |
Est. primary completion date | April 27, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: (For Dose Escalation and Dose Expansion) - Subjects must have a tumor positive for Nectin-4 expression (as measured by central laboratory using primary or metastatic tumor tissue - Histologically confirmed malignant solid tumors (excluding sarcoma) that have failed all FDA approved therapies indicated for the type of metastatic cancer and line of therapy or for which they were not a candidate to receive treatment - Measurable disease according to RECIST criteria (version 1.1) (Eisenhauer, et. al.) defined as tumor lesions that are accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: - 10mm by CT scan (CT scan slice thickness no greater than 5mm - 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as nonmeasurable - 20 mm by chest X-ray - = 15 mm in short axis for lymph nodes when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) Note: bone lesions, ascites, and pleural effusions are not considered measurable lesions - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Negative pregnancy test (women of childbearing potential) - Hematologic function, as follows: - a. Absolute neutrophil count (ANC) = 1.0 x109 /L - b. Platelet count = 100 x 109/L - c. Hemoglobin = 8.5 g/dL - Renal function, as follows: serum creatinine = 2.0 mg/dL, or measured 24 hour creatinine clearance of = 45 mL/min - Total bilirubin =1.5 x upper limit of normal (ULN) - Serum albumin > 2.5 g/dL - Aspartate aminotransferase (AST) = 1.5 x ULN - Alanine aminotransferase (ALT) = 1.5 x ULN - Gamma GT =1.5 ULN - International normalized ratio (INR) < 1.5 (or = 3 if on warfarin or other medications for therapeutic anticoagulation) - Women and men of childbearing potential must be advised and agree to practice effective methods of contraception during the course of the study Inclusion Criteria for Dose Expansion Only: In addition to the inclusion criteria listed above, the following criteria will also be required for each expansion cohort: Expansion Cohort 1: Breast Cancer - Subjects with Histologically or cytologically diagnosed metastatic breast cancer Expansion Cohort 2: Bladder Cancer - Histologically or cytologically confirmed bladder cancer with visceral metastases Expansion Cohort 3: Lung plus other solid tumor cancer - Histologically or cytologically confirmed metastatic non-small cell lung cancer (NSCLC) or any other solid tumor cancer Exclusion Criteria: - Preexisting neuropathy Grade = 3 or motor neuropathy Grade = 2 - Uncontrolled brain or epidural spinal metastases - Use of any investigational drug within 14 days or 5 half-lives prior to first dose of study drug - Any anticancer therapy including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer within 28 days prior to first dose of study drug - Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of the first dose of study drug, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by medication - Known HIV or AIDS - Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy - History of thromboembolic events and bleeding disorders = 3 months (e.g.,deep vein thrombosis ( DVT) or pulmonary embolism ( PE)) prior to first dose of study drug - Major surgery within 28 days prior to first dose of study drug - Active infection requiring treatment =7 days prior to first dose of study drug - Anti-androgen therapy initiated within 28 days of enrollment (for prostate cancer patients only) - Positive Hepatitis B surface antigen test - Positive Hepatitis C antibody test |
Country | Name | City | State |
---|---|---|---|
Canada | Cross Cancer Institute | Edmonton | Alberta |
United States | Emory University | Atlanta | Georgia |
United States | University of Colorado, Denver-Aurora | Aurora | Colorado |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | University of North Carolina, Chapel Hill | Chapel Hill | North Carolina |
United States | Karmanos Cancer institute | Detroit | Michigan |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc | Agensys, Inc., Seagen Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events | Up to 28 days after the last dose of study drug | ||
Primary | Composite of Pharmacokinetics: Ceoi or Cmax, Ctrough, Tmax, AUC0-21, t½, CL, Vss | Concentration at the end of infusion (Ceoi) or Cmax, trough concentration (Ctrough), Tmax, partial AUC after first dose (AUC0-21), terminal or apparent terminal half-life (t1/2), systemic clearance (CL), volume of distribution at steady state (Vss) | Up to 28 days after the last dose of study drug | |
Secondary | Incidence of anti-drug antibody formation | Up to 28 days after the last dose of study drug | ||
Secondary | Objective tumor response rate | Incidence of a tumor response is defined as a complete or partial response per Response Criteria for Solid Tumors (RECIST version 1.1) | Every 8 weeks (± 14 days) | |
Secondary | Disease Control Rate | Every 8 weeks (± 14 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |